Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,509 shares of the medical research company’s stock after selling 3,346 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $16,871,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Signature Resources Capital Management LLC raised its holdings in Thermo Fisher Scientific by 318.2% in the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 35 shares during the last quarter. Northwest Financial Advisors purchased a new position in Thermo Fisher Scientific during the fourth quarter worth approximately $29,000. True Wealth Design LLC grew its holdings in Thermo Fisher Scientific by 1,275.0% in the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after buying an additional 51 shares in the last quarter. New Millennium Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth $29,000. Finally, LifeSteps Financial Inc. purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $31,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Wells Fargo & Company began coverage on Thermo Fisher Scientific in a research note on Tuesday. They set an “overweight” rating and a $670.00 target price for the company. HSBC lifted their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Evercore ISI dropped their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Finally, Stifel Nicolaus increased their price target on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $630.41.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $611.03, for a total transaction of $525,485.80. Following the completion of the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at approximately $1,108,408.42. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,084 shares of company stock valued at $19,767,092. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Up 0.8 %

Shares of TMO stock opened at $610.40 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $622.30. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The business’s fifty day moving average price is $574.90 and its 200 day moving average price is $574.35. The firm has a market capitalization of $233.17 billion, a PE ratio of 39.15, a P/E/G ratio of 2.81 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter last year, the business earned $5.15 earnings per share. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.